Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Kim

Neurological Surgery Houston, TX Medical Doctor

NPI 1275542516 CMS profile 193519

929 Gessner Rd Ste 2410, Houston, TX 77024

Open in the dashboard

General payments

$82,658

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Kim of Houston, TX is reported in the CMS Open Payments database as having received $82,658 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,834 44
2024 General $11,587 47
2023 General $11,917 38
2022 General $4,751 13
2021 General $18,435 13
2020 General $13,013 7
2019 General $14,122 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Kim
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Daniel Kim were reported at $8,834. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Daniel Kim Neurological Surgery median Middle half National median
2019 $14,122 $582 $138–$3,006 $163
2020 $13,013 $294 $76–$2,174 $114
2021 $18,435 $387 $105–$2,432 $132
2022 $4,751 $542 $139–$2,989 $149
2023 $11,917 $534 $145–$2,697 $160
2024 $11,587 $574 $155–$3,046 $164
2025 $8,834 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Products, Inc. $65,060 29 payments
  2. Intuitive Surgical, Inc. $7,886 8 payments
  3. Stryker Corporation $3,846 61 payments
  4. Medtronic, Inc. $1,244 16 payments
  5. Boston Scientific Corporation $1,236 4 payments
  6. VB Spine LLC $1,208 25 payments
  7. Nevro Corp. $897 11 payments
  8. Globus Medical, Inc. $224 5 payments
  9. Zimvie Inc. $206 2 payments
  10. Cerapedics, Inc. $166 1 payment
  11. Other $686 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $65,060 29 payments
  2. Education $7,000 2 payments
  3. Food and Beverage $6,828 127 payments
  4. Travel and Lodging $2,592 12 payments
  5. Current or prospective ownership or investment interest $1,177 3 payments
Products named General payments · program years 2019–2025
  1. EXPEDIUM Spine $39,478 21 payments
  2. EXPEDIUM Spine $25,582 8 payments
  3. Da Vinci Surgical System Surgery $7,000 2 payments
  4. EVEREST SPINAL SYSTEM $2,281 18 payments
  5. General Therapies $1,080 1 payment
  6. INTELLIS ADAPTIVESTIM $996 14 payments
  7. Da Vinci Surgical System Surgery $886 6 payments
  8. Senza $751 10 payments
  9. XIA 3 Spine $633 12 payments
  10. XIA 3 Thoracolumbar $357 11 payments
  11. Other $3,658 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

711

Median for Neurosurgery: 83

Drug cost

$7,355

Median for Neurosurgery: $872

Branded share of claims

45.7%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 303 $4,768
Cyclobenzaprine Hcl Generic 175 $893
Gabapentin Generic 67 $493
Methylprednisolone Generic 51 $360
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $342
Meloxicam Generic 48 $172
Duloxetine Hcl Generic 19 $161
Diclofenac Sodium Generic 11 $132
Tramadol Hcl Generic 15 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$185,985

Medicare's payments for the services billed

Medicare patients

242

Average age 72

Services billed

709

145 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 31%
Depression 25%
Chronic kidney disease 22%
Osteoporosis 21%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record